



Financial Tear Sheet


Corporate Profile

Athenex is a global oncology focused biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, aiming to develop safer and more efficacious cancer medication.

Founded in 2003 and based in Buffalo, New York, our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. We are focused on generating clinical candidates focused on oral delivery, and currently have 7 products including one currently in phase 3 and another for which we will soon commence a phase 3 study.

Our seasoned management team has a proven track record in drug development and commercialization, including several former industry CEOs. We have the experience and capabilities to leverage our proprietary research and development platforms to produce candidates and move them throughout candidacy to market.

We have organized our business model into three segments: Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform—with operations in both the U.S. and China. Our global operations across the three segments are shown below:



Our Global Supply Chain Platform manufactures active pharmaceutical ingredients, or API, for use internally in our research and development, clinical studies, and for sale to pharmaceutical customers globally. Our Commercial Platform currently markets the API produced by our Global Supply Chain Platform, including 14 products in the specialty and generic market segment in the U.S. and products under Section 503B of the Food, Drug and Cosmetics Act, or FDCA, through our compound pharmacy facility.

Primary IR Contact

Chief Financial Officer
Nick Riehle
Phone: 716-427-2952

Stock Performance

ATNX (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$16.66**

Change (%) **▼ 0.11 (0.66%)**

Volume 1,754,170

52 Week High \$20.79

52 Week Low \$11.21

Market Cap \$1,041,837,498

Rolling EPS -2.76

PE Ratio 0

Shares Outstanding 62,535,264

Data as of Feb 16, 2018 4:00 p.m. ET



Recent Headlines

February 16, 2018

[Athenex to Present at 2018 RBC Capital Markets Healthcare Conference](#)

February 15, 2018

[Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer](#)

February 14, 2018

[Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
Feb 09, 2018	<u>4</u>
Feb 09, 2018	<u>4</u>
Feb 09, 2018	<u>4</u>
Feb 06, 2018	<u>4</u>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Corporate Governance
